• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    12/15/25 8:03:33 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIXC alert in real time by email
    false 0001460702 0001460702 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 12, 2025

     

    AIxCrypto Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37428   26-3474527
    (State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
    of incorporation)       Identification No.)

     

    5857 Owens Avenue, Suite 300    
    Carlsbad, California   90248
    (Address of principal executive offices)   (Zip Code)

     

    (760) 452-8111

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Class A common stock, par value $0.0001 per share   AIXC   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    On December 12, 2025, the Audit Committee of the Board of Directors of AIxCrypto Holdings, Inc., a corporation incorporated under the laws of the State of Delaware (the “Company”) terminated Macias Gini & O’Connell LLP (“MGO”) as the independent registered public accounting firm of the Company.

     

    During the Company’s two most recent fiscal years and the subsequent interim period through December 12, 2025, there were no disagreements with MGO on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of MGO, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report. During the Company’s two most recent fiscal years and the subsequent interim period through December 12, 2025, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K.

     

    The Company provided MGO with a copy of the foregoing disclosure and requested MGO to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of such letter furnished by MGO is filed as Exhibit 16.1 to this Form 8-K.

     

    On December 12, 2025, the Company’s Audit Committee approved the engagement of HTL International, LLC (“HTL”) as the Company’s new independent registered public accounting firm.

     

    During the Company’s two most recent fiscal years and the subsequent interim period through December [10], 2025, neither the Company nor anyone on its behalf consulted with HTL regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided that HTL concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K:

     

    No.   Description of Exhibits
    16.1   Letter from Macias Gini & O’Connell LLP
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AIXCRYPTO HOLDINGS, INC.
       
    Date: December 15, 2025 By: /s/ Koti Meka
      Name: Koti Meka
      Title: Chief Financial Officer

     

    3

     

    Get the next $AIXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing Progress

    LOS ANGELES, April 6, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) and on-chain asset ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting continued progress in the Company's AI Agent strategy, including ongoing development across key modules and the start of initial internal enterprise testing aimed at supporting workflow optimization and practical use case refinement. Advancing AI Agent-Related Development EffortsThis week, AIxC continued to advance its broader AI Agent strategy, with development work across key modules and supporting i

    4/6/26 11:42:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Highlights Full Year 2025 Transformation and Next Phase of Growth

    LOS ANGELES, March 30, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI ("EAI") ecosystem, today highlighted key takeaways from its recently released full year 2025 results and provided an update on the Company's continued strategic development. Annual Report HighlightsFiscal year 2025 marked a foundational year for AIxC's strategic transformation. As outlined in the Company's annual results, AIxC completed its transition toward AI- and blockchain-enabled digital infrastructure, strengthened its capital position through financing activities, including the completion of a $41.0 million PIPE

    3/30/26 4:48:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    SEC Filings

    View All

    SEC Form 10-K filed by AIxCrypto Holdings Inc.

    10-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/30/26 6:21:26 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/27/26 4:30:35 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/27/26 4:05:53 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Financials

    Live finance-specific insights

    View All

    FF Announces Fourth Quarter and Full Year 2025 Financial Results: Stockholders' Equity Turns Positive; First Month of EAI Robotics Delivery Beats Target with Positive Product Gross Margin

    Balance sheet strengthens with return to positive stockholders' equity following ~$100 million debt optimization. EAI robotics exceeds target of shipping 20 units in its first delivery month and achieves positive product gross margins in Q1 2026, establishing a scalable growth and cash flow engine, targeting cumulative shipments of more than 1,000 units by the end of December 2026. The Company expects to generate software-related revenue beyond device sales within 2026. EAI EV Strategy advances into validation and pre-production with a disciplined, cash-aligned ramp. FF is the first U.S. company to deliver both humanoid and bionic robots that utilize a self-reinforcing "Device-Dat

    3/31/26 5:23:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: IR@aixcrypto.ai. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials